Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Fulvestrant + PF-07220060|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fulvestrant||Faslodex||ICI 182,780||Hormone - Anti-estrogens 22||Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov).|
|PF-07220060||PF 07220060|PF07220060||CDK4 Inhibitor 14||PF-07220060 inhibits CDK4 and may lead to cell cycle arrest and inhibition of tumor cell proliferation (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04557449||Phase I||Letrozole + PF-07220060 Fulvestrant + PF-07220060 PF-07220060||Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4)||Recruiting||USA||0|